Real World ETNA Registries of New Once-Daily LIXIANA® (edoxaban) Start in Europe (y 2)

Publicado 24/08/2015 7:00:50CET

AF, a heart rhythm disorder in which the heartbeat is rapid and irregular, affects over six million Europeans.[7] People with AF are at a five-fold increased risk of stroke compared to the general population,[7] with an estimated financial burden of over EUR38 billion a year.[8] VTE, a condition where a blood clot forms in a vein, also represents a major cause of morbidity and mortality, resulting in over 500,000 deaths in the EU each year.[9]

About Daiichi Sankyo  

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group's research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: http://www.daiichisankyo.com.

Forward-looking statements 

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References 

1) Giugliano R, et al. Edoxaban versus warfarin in patients with atrial fibrillation.

N Engl J Med. 2013;369(22):2093-104.

2) Büller H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous

thromboembolism. N Engl J Med. 2013;369(15):1406-15.

3) Daiichi Sankyo press release - Daiichi Sankyo's Once-Daily Lixiana(R) (edoxaban)

Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial

Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism

in Switzerland. 15 April 2015. Available at:

http://www.daiichisankyo.com/media_investors/media_relations...

[Last accessed: August 2015].

4) Daiichi Sankyo press release - Daiichi Sankyo Receives Approval for Additional

Indications of LIXIANA(R) (edoxaban) in Japan. 26 September 2014. Available at:

http://www.daiichisankyo.com/media_investors/media_relations...

. [Last accessed: August 2015].

5) Daiichi Sankyo press release - Daiichi Sankyo launches LIXIANA(R) (edoxaban), a direct

oral factor Xa inhibitor, in Japan for the prevention of venous thromboembolism after

major orthopaedic surgery. 19 July 2011. Available at:

http://www.daiichisankyo.com/media_investors/media_relations...

. [Last accessed: August 2015].

6) Daiichi Sankyo press release - U.S. FDA Approves Daiichi Sankyo's Once-Daily SAVAYSA

(TM) (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial

Fibrillation and for the Treatment of Venous Thromboembolism - 8 January 2015.

Available at:

http://www.daiichisankyo.com/media_investors/media_relations...

[Last accessed: August 2015].

7) Camm A, et al. Guidelines for the management of atrial fibrillation: the Task Force

for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Eur Heart J. 2010;31(19):2369-429.

8) Allender S, Scarborough P, Peto V, et al. European Cardiovascular Disease Statistics

2012 Edition.

9) Cohen AT, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and

associated morbidity and mortality. Thromb Haemost. 2007;756-764: doi:10.1160/TH07.

 

Contact

 

Lydia Worms (Europe) 

Daiichi Sankyo Europe GmbH 

Edoxaban Comm. & Product PR Europe 

+49(89)7808751

 

Yasuki Minobe (Global) 

Daiichi Sankyo Group 

Corporate Communications Department 

+81(3)62251126

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación